Market Overview

UPDATE: Stifel Reiterates On HealthSouth As Second Quarter Easily Exceeds Projection

Related HLS
Benzinga's Top Downgrades
Healthsouth 8-K Reaffirms 2015 Guidance
HealthSouth: The Market Overreaction Has Created A Buying Opportunity (Seeking Alpha)

In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth (NYSE: HLS), and raised the price target from $38.00 to $41.00.

In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.”

HealthSouth closed on Monday at $37.64.

Latest Ratings for HLS

Oct 2015SunTrust Robinson HumphreyMaintainsBuy
Oct 2015BarclaysMaintainsEqualweight
Oct 2015Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for HLS
View the Latest Analyst Ratings

Posted-In: Robert Mains StifelAnalyst Color Price Target Analyst Ratings


Related Articles (HLS)

Get Benzinga's Newsletters